Amyloid precursor protein expression is enhanced in human platelets from subjects with Alzheimer's disease and frontotemporal lobar degeneration: A Real-time PCR study

Experimental Gerontology

Volumn 48, Issue 12, 2013, Pages 1505-1508

  Vignini, Arianna ^a   Morganti, Stefano ^a   Salvolini, Eleonora ^a   Sartini, Davide ^a   Luzzi, Simona ^a   Fiorini, Rosamaria ^a   Provinciali, Leandro ^a   Di Primio, Roberto ^a   Mazzanti, Laura ^a   Emanuelli, Monica ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Alzheimer; Amyloid precursor protein; Frontotemporal lobar degeneration; Platelets; Real time PCR

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; SECRETASE; SERINE PROTEINASE INHIBITOR;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME SYNTHESIS; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMAN; HUMAN CELL; MALE; MUTATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; UPREGULATION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; BLOOD PLATELETS; CASE-CONTROL STUDIES; COGNITION; DIAGNOSIS, DIFFERENTIAL; FEMALE; FRONTOTEMPORAL LOBAR DEGENERATION; GENETIC MARKERS; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; UP-REGULATION;

EID: 84887398453     PISSN: 05315565     EISSN: 18736815     Source Type: Journal    
DOI: 10.1016/j.exger.2013.10.008     Document Type: Article

References (27)

1. Amtul Z., Lewis P.A., Piper S., Crook R., Baker M., Findlay K., Singleton A., Hogg M., Younkin L., Younkin S.G., Hardy J., Hutton M., Boeve B.F., Tang-Wai D., Golde T.E. A presenilin 1 mutation associated with familial frontotemporal dementia inhibits γ-secretase cleavage of APP and notch. Neurobiol. Dis. 2002, 9:269-273.
2. Armstrong M.J., Litvan I., Lang A.E., Bak T.H., Bhatia K.P., Borroni B., Boxer A.L., Dickson D.W., Grossman M., Hallett M., Josephs K.A., Kertesz A., Lee S.E., Miller B.L., Reich S.G., Riley D.E., Tolosa E., Tröster A.I., Vidailhet M., Weiner W.J. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013, 80:496-503.
3. Ballatore C., Lee V.M., Trojanowski J.Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci. 2007, 8:663-672.
4. Bird T., Knopman D., VanSwieten J., Rosso S., Feldman H., Tanabe H., Graff-Raford N., Geschwind D., Verpillat P., Hutton M. Epidemiology and genetics of frontotemporal dementia/Pick's disease. Ann. Neurol. 2003, 54(Suppl. 5):S29-S31.
5. Braak H., Braak E. Morphological criteria for the recognition of Alzheimer's disease and the distribution pattern of cortical changes related to this disorder. Neurobiol. Aging 1994, 15:355-356.
6. Buoso E., Lanni C., Schettini G., Govoni S., Racchi M. Beta-Amyloid precursor protein metabolism: focus on the functions and degradation of its intracellular domain. Pharmacol. Res. 2010, 62:308-317.
7. Cattabeni F., Colciaghi F., Di Luca M. Platelets provide human tissue to unravel pathogenic mechanisms of Alzheimer disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28:763-770.
8. Cummings J.L., Askin-Edgar S. Evidence for psychotropic effects of acetylcholinesterase inhibitors. CNS Drugs 2000, 13:385-395.
9. Davies T.A., Long H.J., Sgro K., Rathbun W.H., Mcmenamin M.E., Seetoo K., Tibbles H., Billingslea A.M., Fine R.E., Fishman J.B., Levesque C.A., Smith S.J., Wells J.M., Simons E.R. Activated Alzheimer disease platelets retain more beta amyloid precursor protein. Neurobiol. Aging 1997, 18:147-153.
10. Di Luca M., Colciaghi F., Pastorino L., Borroni B., Padovani A., Cattabeni F. Platelets as a peripheral district where to study pathogenetic mechanisms of Alzheimer disease: the case of amyloid precursor protein. Eur. J. Pharmacol. 2000, 405:277-283.
11. Donovan L.E., Dammer E.B., Duong D.M., Hanfelt J.J., Levey A.I., Seyfried N.T., Lah J.J. Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer's disease. Alzheimers Res. Ther. 2013, 5:32-47.
12. Folstein M.F., Folstein S.E., McHugh P.R. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975, 12:189-198.
13. Golde T.E., Younkin S.G. Presenilins as therapeutic targets for the treatment of Alzheimer's disease. Trends Mol. Med. 2001, 7:264-269.
14. Ikeda M., Ishikawa T., Tanabe H. Epidemiology of frontotemporal lobar degeneration. Dement. Geriatr. Cogn. Disord. 2004, 17:265-268.
15. Kertesz A., Martinez-Lage P., Davidson W., Munoz D.G. The corticobasal degeneration syndrome overlaps progressive aphasia and frontotemporal dementia. Neurology 2000, 55:1368-1375.
16. Lee V.M., Goedert M., Trojanowski J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 2001, 24:1121-1159.
17. Matsui T., Ingelsson M., Fukumoto H., Ramasamy K., Kowa H., Frosh M.P., Irizarry M.C., Hyman B.T. Expression of APP pathway mRNAs and proteins in Alzheimer's disease. Brain Res. 2007, 1161:116-123.
18. McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jr C.R., Jack C.H., Kawas W.E., Klunk W.J., Koroshetz J.J., Manly R., Mayeux R.C., Mohs J.C., Morris M.N., Rossor P., Scheltens M.C., Carrillo B., Thies S., Weintraub C.H.Phelps The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:263-269.
19. Neary D., Snowden J.S., Gustafson L., Passant U., Stuss D., Black S., Freedman M., Kertesz A., Robert P.H., Albert M., Boone K., Miller B.L., Cummings J., Benson D.F. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998, 51:1546-1554.
20. Seelaar H., Rohrer J.D., Pijnenburg Y.A.L., Fox N.C., van Swieten J.C. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J. Neurol. Neurosurg. Psychiatry 2011, 82:476-486.
21. Smith C.C., Prichard B.N., Cooper M.B. Platelet alpha- and beta-secretase activities: a preliminary study in normal human subjects. Platelets 2009, 20:29-34.
22. Steinacker P., Hendrich C., Sperfeld A.-D., Jesse S., Lehnert S., Pabst A., von Arnim C.A.F., Mottaghy F.M., Uttner I., Tumani H., Ludolph A., Otto M. Concentrations of beta-amyloid precursor protein processing products in cerebrospinal fluid of patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration. J. Neural Transm. 2009, 116:1169-1178.
23. Tang K., Hynan L.S., Baskin F., Rosenberg R.N. Platelet amyloid precursor protein processing: a bio-marker for Alzheimer's disease. J. Neurol. Sci. 2006, 240:53-58.
24. Vignini A., Nanetti L., Moroni C., Tanase L., Bartolini M., Luzzi S., Provinciali L., Mazzanti L. Modifications of platelet from Alzheimer disease patients: a possible relation between membrane properties and NO metabolites. Neurobiol. Aging 2007, 28:987-994.
25. Vignini A., Sartini D., Morganti S., Nanetti L., Luzzi S., Provinciali L., Mazzanti L., Emanuelli M. Platelet amyloid precursor protein isoform expression in Alzheimer's disease: evidence for peripheral marker. Int. J. Immunopathol. Pharmacol. 2011, 24:529-534.
26. Vignini A., Giusti L., Raffaelli F., Giulietti A., Salvolini E., Luzzi S., Provinciali L., Mazzanti L., Nanetti L. Impact of gender on platelet membrane functions of Alzheimer's disease patients. Exp. Gerontol. 2013, 48:319-325.
27. Zhang Y.W., Thompson R., Zhang H., Xu H. APP processing in Alzheimer's disease. Mol. Brain 2011, 4:3.